A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses
NCT07330674
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 1 study to evaluate the safety, tolerability, PK, and PD of ABF-101 in healthy participants and participants with age-related macular degeneration (AMD).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Age Related Macular Degeneration (ARMD)
- AMD - Age-Related Macular Degeneration
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Aptabio Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- February 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 1
- Dallas Clinical Research Unit · Dallas, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.